Methylphenidate for ADHD in Pediatric Epilepsy

This trial aims to observe how methylphenidate hydrochloride (Jornay PM) works for children with both ADHD (attention deficit hyperactivity disorder) and epilepsy. The goal is to understand the effects of this stimulant medication in children who need seizure medicine but also struggle with ADHD symptoms. Children with stable epilepsy, a diagnosis of ADHD, and no recent severe seizures might be suitable candidates for this study. As a Phase 4 trial, the research focuses on understanding how this FDA-approved and effective treatment can benefit more patients.

The trial does not specify if you need to stop taking your current medications, but it does require that you are not currently using stimulants to treat ADHD. You should discuss your specific medications with the study team to be sure.

Research has shown that Jornay PM (methylphenidate hydrochloride) is safe and effective for treating ADHD in children aged 6 to 17. The FDA has approved it for this use. Studies have also found that methylphenidate is safe for children with ADHD who also have epilepsy or unusual brain activity patterns.

Common side effects include headaches and increased activity levels, occurring in about 5% of children taking the medication—twice as often as those taking a placebo (a sugar pill used in testing).

Methylphenidate hydrochloride (Jornay PM) is unique because it offers a new way of managing ADHD symptoms in children with epilepsy. Unlike traditional stimulants, which can exacerbate seizure risks, Jornay PM provides a controlled release of methylphenidate throughout the day, potentially minimizing these risks. Researchers are excited because this formulation might allow for ADHD symptom control without increasing the likelihood of seizures, offering a safer option for this sensitive patient population.

Research has shown that Jornay PM, a form of methylphenidate hydrochloride, helps treat ADHD. Studies have found that this medication significantly improves ADHD symptoms. Specifically, one study noted that 73% of patients no longer had significant symptoms after three months. Jornay PM is approved for children aged 6 to 17 and effectively manages ADHD symptoms throughout the day. Research also indicates it is safe for children with epilepsy, which is crucial for those considering this treatment. Overall, the evidence supports its effectiveness and safety for managing ADHD in children, including those with epilepsy.⁴⁵⁶⁷⁸